Last $4.71 USD
Change Today -0.01 / -0.21%
Volume 4.1K
HBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:13 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Open
$4.71
Previous Close
$4.72
Day High
$4.71
Day Low
$4.68
52 Week High
12/20/13 - $5.15
52 Week Low
06/25/14 - $3.68
Market Cap
152.1M
Average Volume 10 Days
58.7K
EPS TTM
$0.10
Shares Outstanding
32.3M
EX-Date
--
P/E TM
47.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARVARD BIOSCIENCE INC (HBIO)

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis and autoradiography products, thermal cycler accessories and reagents, general lab equipment and consumables, and tissue culture products primarily under the Denville Scientific, Hoefer, and Scie-Plas brands. It also provides molecular analysis products, such as spectrophotometers under the UltroSpec, NovaSpec, Libra, and BioDrop brands; microplate readers under the Asys Hitech and Anthos Labtec brands; and amino acid analyzers under the Biochrom brand. In addition, the company offers electroporation and electrofusion products comprising systems and generators, electrodes, and accessories under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamps, amplifiers, bilayer workstations, temperature controllers, chambers, and accessories under the Warner Instrument brand. Further, it provides physiology products, which include a range of instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research products, isolated perfused organ and tissue bath systems, and research-based regenerative medicine products under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, and InBreath Bioreactor brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies through catalogs, distributors, direct sales force, and its Websites. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

345 Employees
Last Reported Date: 03/14/14
Founded in 1901

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $271.8K
Co-Founder and Director
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $54.8K
Vice President of Strategic Marketing and Bus...
Total Annual Compensation: $64.5K
Vice President of Global Sales
Total Annual Compensation: $34.0K
Compensation as of Fiscal Year 2013.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Year 2014

Harvard Bioscience Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. Revenues for the three months ended June 30, 2014 were $27.0 million, an increase of approximately $0.9 million, or 3.3% compared to revenues of $26.1 million for the three months ended June 30, 2013. Of the overall increase in revenues, currency translation, due to a weaker U.S. dollar compared to the British pound sterling and the Euro, accounted for a 2.6% positive impact. Income from continuing operations was $1.0 million, or $0.03 per diluted share, for the three months ended June 30, 2014 compared to $0.1 million, or $0.00 per diluted share, for the same quarter in 2013. Income from continuing operations, on a non-GAAP basis, was $1.9 million, or $0.06 per diluted share, for the three months ended June 30, 2014, unchanged compared to the three months ended June 30, 2013. Excluding the impact of currency translation, operating income on a GAAP and non-GAAP basis would have been lower by $0.1 million during the three months ended June 30, 2014 compared to the three months ended June 30, 2013. Operating income was $1,738,000 against $747,000 for the same period of last year. Income from continuing operations before income taxes was $1,270,000 against income of $418,000 for the same period of last year. Non-GAAP adjusted operating income was $2,930,000 compared to $2,988,000 a year ago. Revenues for the six months ended June 30, 2014 were $52.9 million, an increase of approximately $0.7 million, or 1.3% compared to revenues of $52.2 million for the six months ended June 30, 2013. Overall, currency translation had a 2.3% positive impact. Income from continuing operations was $1.7 million, or $0.05 per diluted share, for the six months ended June 30, 2014 compared to $1.0 million, or $0.03 per diluted share, for the same period in 2013. Overall, the favorable year-to-year GAAP earnings comparison was due primarily to transaction costs incurred during the six months ended June 30, 2013. Income from continuing operations, on a non-GAAP basis, was $3.6 million, or $0.11 per diluted share, for the six months ended June 30, 2014 compared to $4.0 million, or $0.13 per diluted share, for the same period in 2013. Excluding the impact of currency translation, operating income on a GAAP and non-GAAP basis would have been lower by $0.2 million during the six months ended June 30, 2014 compared to the six months ended June 30, 2013. Operating income was $3,072,000 against $2,072,000 for the same period of last year. Income from continuing operations before income taxes was $2,289,000 against income of $1,645,000 for the same period of last year. Net cash provided by operating activities was $2,486,000 compared to $1,380,000 a year ago. Non-GAAP adjusted operating income was $5,635,000 compared to $6,122,000 a year ago. Capital expenditures were $744,000 for the 6 months ended June 30, 2014, compared to $584,000 for the same period last year. The increase in capital expenditures this year compared to last year was due to the timing of normal spending on maintenance capital. The company reaffirmed its financial guidance from February 27, 2014, which included revenues of approximately $105 million, and anticipates 2014 will be a bridge year to return the company to top-line growth in 2015. The company expects to report full-year 2014 non-GAAP income from continuing operations of $0.26 per diluted share. This translates to GAAP income from continuing operations of $0.14 per diluted share.

Harvard Bioscience Inc. to Report Q2, 2014 Results on Jul 31, 2014

Harvard Bioscience Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 31, 2014

Harvard Bioscience Inc., Q2 2014 Earnings Call, Jul 31, 2014

Harvard Bioscience Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $4.71 USD -0.01

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $124.39 USD +1.08
Bio-Rad Laboratories Inc $112.60 USD -0.21
Danaher Corp $76.36 USD +0.11
PerkinElmer Inc $40.91 USD -0.78
Thermo Fisher Scientific Inc $114.09 USD -4.13
View Industry Companies
 

Industry Analysis

HBIO

Industry Average

Valuation HBIO Industry Range
Price/Earnings 100.0x
Price/Sales 1.4x
Price/Book 1.5x
Price/Cash Flow 62.0x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit www.harvardbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.